NCT03892577 - Real-world Study for Patients With Advanced Hepatobiliary Tumors | Biotech Hunter

Enrollment

3,000

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

October 1, 2023

Study Completion Date

December 31, 2025

Conditions

Objective Response RateProgression-free SurvivalOverall SurvivalDisease Control RateDuration of ResponseFive-year Survival RateQuality of Life

Interventions

DRUG

Precision oncology including targeted therapy and immunotherapy

Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.

Trial Locations (1)

100730

RECRUITING

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing